21 July 2023>: Articles
A Case of Hemorrhagic Cholecystitis in a Patient on Apixaban After COVID-19 Infection
Unknown etiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy
Zohour Anouassi A , Carlos Abril A , Ghanem Ismail A , Wasim S. El Nekidy A , Abdullah Al-Hadeethi A , Ahmed Bafadel A , Bassam Atallah A*DOI: 10.12659/AJCR.939677
Am J Case Rep 2023; 24:e939677
Table 1. Patient laboratory values on presentation to the emergency room.
Lab | Ref. range | During ED (15/3/2022) | Day 1 (16/3) | Day 3 (17/3) | Day 4 (18/3) |
---|---|---|---|---|---|
Alkaline phosphatase | 40–129 U/L | 588 (H) | 532 (H) | 368 (H) | 295 (H) |
ALT | 17–63 U/L | 539 (H) | 546 (H) | 300 (H) | 209 (H) |
AST | 0–39 U/L | 265 (H) | 541 (H) | 78 (H) | 40 (H) |
Total Bilirubin | 5–21 micromol/L | 42 (H) | 41 (H) | 15 | 13 |
Creatinine, Ser | 59–104 micromol/L | 61 | 65 | 73 | |
eGFR | ≥60 mL/min/1.73 m | >60 | >60 | >60 | |
Hemoglobin | 126–174 g/L | 78 (L) | 67 (L) | 73 (L) | 81 (L) |
Hematocrit | 0.37–0.51 | 0.27 (L) | 0.23 (L) | 0.25 (L) | 0.27 (L) |
Platelet | 140–400×10/L | 277 | |||
WBC | 4.5–11.0×10/L | 6.6 | 4.8 | 4.0 (L) | 4.2 (L) |
CRP | 0–4.9 mg/dL | 18.8 (H) | 8.4 (H) | ||
PT | 12.8–17.4 sec | 13.9 | |||
INR | 0.8–1.2 ratio | 1 | |||
CA 19-9 | 0–35 kU/L | 288.4 (H) | |||
ALT – alanine aminotransferase; AST – aspartate aminotransferase; CA19-9 – cancer antigen 19-9; CRP – C-reactive protein; eGFR – estimated glomerular filtration rate; H – high; INR – international normalized ratio; L – low; PT – prothrombin time; WBC – white blood cells. |